Tear levels of macrophage migration inhibitory factor in vernal keratoconjunctivitis

Yıl 2013, Cilt: 4 Sayı: 2, 195 - 198, 01.06.2013

Onur Çatak Orhan Aydemir Bilal Üstündağ

https://doi.org/10.5799/ahinjs.01.2013.02.0264

https://izlik.org/JA84RX89HK

Öz

Objective: The pathogenesis of vernal keratoconjunctivi­tis (VKC) is not fully understood and cannot be explained only with type I hypersensitivity reaction. The aim of this study was to determine the Macrophage migration inhibi­tory factor (MIF) levels in tear fluids of patients with VKC. Methods: Tear fluid samples were collected with micro­capillary tubes for hematocrit at the lateral canthus of patients in the supine position without any anesthesia. Tear levels of MIF were measured by ELISA kit. Tear fluid samples were collected from 10 healthy subjects and 20 patients with VKC. Results: Tear levels of MIF in patients with VKC were significantly higher than those in controls (p

Anahtar Kelimeler

Macrophage migration inhibitory factor , ver­nal keratoconjunctivitis , ELISA

Vernal keratokonjonktivitte gözyaşı makrofaj migrasyon inhibitör faktör düzeyleri

https://izlik.org/JA84RX89HK

Öz

Amaç: Vernal keratokonjonktivitin (VKC) patogenezi tam olarak anlaşılamamış olup, sadece Tip I aşırı duyarlılık cevabıyla açıklanamamaktadır. Bu çalışmada VKC hasta­larının gözyaşı makrofaj migrasyon inhibitör faktör (MIF) düzeyini araştırmak amaçlanmıştır. Yöntemler: Gözyaşı örnekleri topikal anestezi damlatma­dan lateral kantusa yerleştirilen hematokrit tüplerine alın­dı. MIF düzeyleri ELISA yöntemi ile incelendi. Çalışmaya 20 VKC hastası ve 10 sağlıklı birey dahil edildi. Sonuç: Kontrol grubu ile karşılaştırıldığında VKC\'li hasta­larda gözyaşı MIF seviyeleri anlamlı olarak daha yüksek bulundu (p

Anahtar Kelimeler

Makrofaj migrasyon inhibitör faktör , vernal keratokonjonktivit , ELISA

Kaynakça

• Bonini S, Bonini S, Lambiase A, et al. Vernal keratocon- junctivitis revisited. A case series of 195 patients with long-term follow up. Ophthalmology 2000;107:1157- 1163.
• Aragona P, Romeo GF, Puzzolo D, et al. Impression Cytology of the conjunctival epitelium in patients with vernal conjunctivitis. Eye 1996;10:82-85.
• Bloom BR, Bennett B. Mechanism of a reaction in vi- tro associated with delayed-type hypersensitivity. Sci- ence 1966;153:80-82.
• Mitchell R, Bacher M, Bernhagen J. Cloning and char- acterization of the gene for mouse macrophage migra- tion inhibitory factor (MIF). J Immunol 1995;154:3863- 3870.
• Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immu- nol 2003;3:791-800.
• Imamura K, Nishihira J, Suzuki M. Identification and immunohistochemical localization of macrophage mi- gration inhibitory factor in human kidney. Biochem Mol Biol Int 1996;40:1233-1242.
• Shimizu T, Ohkawara A, Nishihira J, Sakamoto W. Identification of macrophage migration inhibitory fac- tor (MIF) in human skin and its immmunohistochemi- cal localization. FEBS Lett 1996;381:199-202.
• Bacher M, Meinhardt A, Lan HY, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998;4:217-230.
• Holmes CL, Russell JA, Walley KR. Genetic polymor- phisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003;124:1103-1115.
• Schroeder S, Borger N, Wrigge H, et al. A tumor ne- crosis factor gene polymorphism influences the in- flammatory response after cardiac operation. Ann Thorac Surg 2003;75:534-537.
• Tomasdottir H, Hjartarson H, Ricksten A, et al. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and in- creased cardiopulmonary morbidity after cardiac sur- gery. Anesth Analg 2003;97:944-949.
• Watanabe E, Hirasawa H, Oda S, et al. Cytokine-re- lated genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J Trauma 2005;59:1181-1189.
• Baugh JA, Donnelly SC. Macrophage migration in- hibitory factor: a neuroendocrine modulator of chronic inflammation. Journal of Endocrinology 2003;179:15- 23.
• Allansmith MR. The eye and immunology. St Louis: Mosby 1982;118-124.
• Coombs RRA, Gell PGH. The classification of aller- gic reactions underlying disease. Gell PGH, Coombs RRA (editors). Clinical aspects of immunology. Ox- ford: Blackwell Scientific Publications. 1962;13-27.
• Johansson SGO, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-824.
• Tomaç N. Allerjik Konjonktivitler. T Klin J Med Sci 2004;24:396-410.
• Thomas LH, Warner JA. The eosinophil and its role in asthma. General Pharmacology 1996;27:593-597.
• Kay AB, Barata L, Meng Q, et al. Eosinophils and eosinophil-associated cytokines in allergic inflamma- tion. International Archives of Allergy and Immunology 1997;113:196-199.
• Rossi AG, Haslett C, Hirani N, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF)-potential role in asthma. Journal of Clini- cal Investigation 1998;101:2869-2874.
• Kitaichi N, Shimizu T, Honda A, et al. Increase in mac- rophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol 2000;244:825-828.
• Nakamaru Y, Oridate N, Nishihira J, et al. Macrophage migration inhibitory factor in allergic rhinitis: its identi- ficationin eosinophils at the site of inflammation. Ann Otol Rhinol Laryngol 2004;113:205-20919. Tomaç N. Allerjik Konjonktivitler. T Klin J Med Sci 2004;24:396- 410.
• Hingorani M, Calder VL, Buckley RJ, Lightman SL. The role of conjunctival epithelial cells in chronic ocu- lar allergic disease. Exp Eye Res 1998;67:491-500.
• Bradding P, Feather IH, Wilson S, et al. Immunolocali- sation of cytokines in the nasal mucosa of normal and perennial rhinitis subject. J Immunol 1993;151:3853- 3865.
• Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996;93:7849-7854.
• Cvetkovic I, Al-Abed Y, Miljkovic D, et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005;146:2942-2951.
• Denkinger CM, Denkinger M, Kort JJ, et al. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune enceph- alomyelitis by impairing the homing of encephalito- genic T cells to the central nervous system. J Immunol 2003;170:1274-1282.
• Matsui Y, Okamoto H, Jia N, et al. Blockade of macro- phage migration inhibitory factor ameliorates experi- mental autoimmune myocarditis. J Mol Cell Cardiol 2004;37:557-566.
• Nicoletti F, Creange A, Orlikowski D, et al. Macro- phage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barre syndrome and experimental allergic neuritis. J Neuroimmunol 2005;168:168-174.
• Yang N, Nikolic-Paterson DJ, Ng YY, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): Potential role of MIF in regulating glucocorti- coid production. Mol Med 1998;4:413-424.